Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial-Reference-Cited by-同舟云学术

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

Published:2015-09 Issue:9 Volume:3 Page:692-701
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Brightling Christopher E,Chanez Pascal,Leigh Richard,O'Byrne Paul M,Korn Stephanie,She Dewei,May Richard D,Streicher Katie,Ranade Koustubh,Piper Edward

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference31 articles.

1. Computed tomography scans in severe asthma: utility and clinical implications;Walker;Curr Opin Pulm Med,2012

2. Costs of asthma are correlated with severity: a 1-yr prospective study;Godard;Eur Respir J,2002

3. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production;Zhu;J Clin Invest,1999

4. Elimination of IL-13 reverses established goblet cell metaplasia into ciliated epithelia in airway epithelial cell culture;Kondo;Allergol Int,2006

5. IL-13-induced airway mucus production is attenuated by MAPK13 inhibition;Alevy;J Clin Invest,2012

Cited by 322 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases;Journal of Inflammation Research;2024-09

2. Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data;Frontiers in Pharmacology;2024-08-13

3. The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma;Biomolecules;2024-05-02

4. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population;The Journal of Allergy and Clinical Immunology: In Practice;2024-05

5. Contemporary Biomarkers in Severe Asthma Management;J BIOL REG HOMEOS AG;2024